Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023606 | 1.00 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL4023603 | 1.00 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL11959639 | 0.94 | TK1 (0.89) | TK1LMNATSHRALBPKM | |
| SCHEMBL11959617 | 0.91 | TK1 (0.83) | TK1LMNATSHRALBPKM | |
| SCHEMBL13464002 | 0.88 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL3618060 | 0.88 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL3616937 | 0.88 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL3618062 | 0.88 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL3616931 | 0.88 | TK1 (1.00) | TK1LMNATSHRALBPKM | |
| SCHEMBL13464001 | 0.88 | TK1 (1.00) | TK1LMNATSHRALBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075917-A1 | THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2010-03-25 | — | — | US | disclosed |
| US-20100075917-A1 | THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2010-03-25 | — | — | US | disclosed |
| EP-1879906-A4 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | ADVANCED GENETIC ANALYSIS CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008059130-A1 | THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS | UNIVERSITE JOSEPH FOURIER (GRENOBLE 1) (FR) | 2008-05-22 | — | — | WO | disclosed |
| EP-1879906-A2 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | AB Advanced Genetic Analysis Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006074351-A2 | REVERSIBLE NUCLEOTIDE TERMINATORS AND USES THEREOF | AGENCOURT PERSONAL GENOMICS (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075917-A1 | THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS | TYMP, PNP, NSUN2 | TK1 19/4885LMNA 788/4885TSHR 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.